Navigation Links
Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms
Date:8/3/2009

WALTHAM, Mass., Aug. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2013 to 2018, generic erosion of established agents--most notably tamsulosin--will cause a decline of more than eight percent in the drug market for benign prostatic hyperplasia and male lower urinary tract symptoms in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Generic erosion will offset market growth of more than seven percent that will be driven by the uptake of emerging agents from 2008 to 2013.

The new Pharmacor report entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms finds that the market is saturated with effective, well-established agents. The market is also concentrated as, in 2008, tamsulosin garnered just over half of all major-market sales for benign prostatic hyperplasia. Tamsulosin, the most widely-used alpha blocker for the indication, is marketed by Boehringer Ingelheim as Flomax/Josir/Alna/Pradif/Urolosin and by Astellas as Omix/Omnic/Flomaxtra/Harnal. Generic versions of tamsulosin have been available in Europe and Japan since 2006 and, in the first half of 2010, the drug will be generically available in the United States as well. As a result of generic competition, tamsulosin's annual major-market sales will plummet 41 percent between 2008 and 2013, according to the report.

The report also finds that, while symptom relief remains the primary concern in treating the disease, drug development for benign prostatic hyperplasia has focused on improving dosing convenience and slowing disease progression. Owing to its dosing convenience, GlaxoSmithKline's tamsulosin/dutasteride fixed-dose combination Duodart will likely increase compliance, while Aeterna Zentaris/Sanofi-Aventis/Shionogi's cetrorelix and Aeterna Zentaris/Spectrum Pharmaceu
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
6. Generic prostate drug helps find high-risk cancers early
7. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
9. FDA Announces Initiative to Bolster Generic Drug Program
10. FDA Struggles to Keep Pace With Requests for Generics
11. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA ... Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs ... guide RNA (sgRNA or crRNA) to create a break in the target DNA that ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... healthcare innovation and investment, announced the two leaders who will deliver keynote presentations ... November 3, at the Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO ...
(Date:9/2/2015)... ... 2015 , ... Telehealth represents a growing trend among Blue Cross and Blue ... of more than 12 Blues plan clients. The September 2015 issue of ... growing trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next ...
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... ambulatory healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing ... “new look” and focus on improving prescriber usability. A leader in health technology, ...
Breaking Medicine News(10 mins):Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2
... Clinic to Automate Three Offices with High Performance DR ... ... /PRNewswire-FirstCall/ - IDC (Imaging Dynamics Company,Ltd.) (TSX: IDL), the global leader ... a contract by,Orthopaedic Clinic of Daytona Beach in Florida for four ...
... Blue Cross ... ... California,(Blue Cross) today announced the inclusion of HealthCare Partners Medical,Group and ... preferred provider, effective January 1, 2008., HealthCare Partners serves more ...
... Feb. 4, 2008 Theres new hope for breast ... place. Researchers at the Texas A&M University College of ... the journals Molecular and Cellular Biology and Carcinogenesis indicating ... in Down Syndrome may also contribute to treating this ...
... Forms Alliance With Veterinary News Network, MODESTO, ... in,veterinary hospital captive audience digital signage solutions and ... one of the,most comprehensive client education systems in ... partnering with emebaVet, bringing interesting,and accurate pet health ...
... Feb. 4 George Abercrombie, president and chief,executive ... Atlanta,business leaders today at a Rotary Club of ... presents businesses with challenges unlike those,anticipated with traditional ... too familiar with preparing for potential,disasters such as ...
... 4 In the first study to directly compare ... indicated overall satisfaction with the vaginal ring, researchers report ... publication of the American College of Obstetricians and Gynecologists. ... birth control pills, these products became available in 2002 ...
Cached Medicine News:Health News:Orthopaedic Clinic of Daytona Beach Chooses IDC for Transition to Digital X-ray 2Health News:HealthCare Partners Physicians Join Blue Cross of California 'Power Select HMO' Network 2Health News:Vet medicine researcher examines link between cancer, Down syndrome 2Health News:emebaVet, LLC Client Education System Gets Bigger and Better in 2008 2Health News:emebaVet, LLC Client Education System Gets Bigger and Better in 2008 3Health News:CEO Addresses Georgia Business Leaders About Developing Pandemic and Business Continuity Plans 2Health News:CEO Addresses Georgia Business Leaders About Developing Pandemic and Business Continuity Plans 3Health News:Ringing endorsement: Women prefer contraceptive ring over patch 2
(Date:9/2/2015)... 2, 2015  The report on breast cancer therapeutics: ... cancer drugs on the basis of the molecules which ... the inner lining of milk ducts or lobules responsible ... of tumor that can spread to other cells present ... in lobules is referred as lobular carcinoma, while the ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... Forecasts Summary Advanced dressings have steadily ... treatment of a variety of wound indications, such ... fluid management, infection control, and physical protection become ... a greater role in standard therapy. This ...
(Date:9/2/2015)... MONROVIA, Calif. , Sept. 2, 2015 STAAR ... and marketer of implantable lenses and delivery systems for the ... William P. Wall to the Company,s Board. ... Abrams Capital, a Boston -based investment firm, ... member of the Board of Directors, and chair of the ...
Breaking Medicine Technology:Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2William P. Wall Appointed to STAAR Surgical Board of Directors 2
... CEL-SCI Corporation,(Amex: CVM ) announced today that it ... its lead drug Multikine(R) on October 8, 2008.,This dedicated ... for,CEL-SCI,s pivotal Phase III clinical trial for first-line therapy ... for,sale following approval of the drug. The facility, which ...
... 0901 is Being Developed as an Oral Dosage Form ... at Improving Glycemic Control in Adults With Type 2 ... (OTCBB: ORMP.OB), a developer of oral drug delivery,systems, announced ... a GLP1-analog., ORMD 0901 belongs to the Incretin ...
Cached Medicine Technology:CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008 2CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008 3Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform 2
... 525 is an assayed quality control ... of blood gas, electrolyte, metabolite, and ... this control makes it the ideal ... It is available in three (3) ...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits....
For the qualitative detection of igG antibodies specific to Helicobacter pylori in human serum, plasma and whole blood specimens...
For the qualitative detection of human occult blood in fecal specimens....
Medicine Products: